

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter S. Linsley et al.  
Serial N .: 09/666,267  
Filed: September 21, 2000  
Docket: 30436.11US06  
Title: LIGAND FOR CD28 RECEPTOR ON B CELLS AND METHODS

CERTIFICATE UNDER 37 CFR §1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on July 23, 2003.

By: Renato Marco P. Dominga  
Name: Renato Marco P. Dominga

55 S. Lake Avenue, Suite 710  
Pasadena, California 91101  
July 23, 2003

MAIL STOP SEQUENCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR §1.8
- ☒ Communication in Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated July 14, 2003
- ☒ Exhibit 1 – Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
- ☒ Exhibit 2 – Computer readable form and paper copy of Sequence Listing and Declaration Under 37 C.F.R. §1.821(f)
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

**MANDEL & ADRIANO**  
55 S. Lake Avenue, Suite 710  
Pasadena, California 91101  
(626) 395-7801

By: Sarah B. Adriano  
Name: Sarah B. Adriano  
Reg. No.: 34,470  
Customer No.: 26,941



DKT. 30436.11US06/SBA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants** : Peter S. Linsley et al.  
**Serial No** : 09/666,267  
**Filed** : September 21, 2000  
**For** : LIGAND FOR CD28 RECEPTOR ON B CELLS AND  
METHODS

55 S. Lake Avenue, Suite 710  
Pasadena, California 91101  
July 23, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
Mail Stop Sequence

SIR:

**COMMUNICATION IN RESPONSE TO NOTICE TO  
COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES DATED JULY 14, 2003**

This Communication is submitted in response to the Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures issued in connection with the above-identified application on July 14, 2003. In accordance with the Notice, the deadline for submitting the Sequence Listing is due on August 14, 2003. Accordingly, this response is being timely filed. A copy of the above-referenced Notice is submitted herein as Exhibit 1.

In the July 14 Communication, the Patent Office requires Applicants to re-submit a computer-readable form (CRF) of the Sequence Listing because the CRF previously submitted on December 12, 2002, was damaged by the sanitation process at the Patent Office.


Applicants wish to point out that this is the third such submission of a diskette containing sequences for the subject application. The diskettes previously submitted on September 23, 2002, and December 12, 2002, were damaged by sanitation processes at the U.S. Patent Office.

Applicants submit herein a substitute Sequence Listing in computer-readable form. Applicants also submit herein a paper copy and a Declaration under 37 C.F.R. §1.821(f) stating that the computer-readable form of the Sequence Listing is identical to the paper copy (attached herewith as Exhibit 2). The substitute Sequence Listing contains no new matter and is supported by the specification as originally filed. Accordingly, its entry is respectfully requested.

Peter S. Linsley et al.  
U.S. Serial No. 09/666,267  
Filed: September 21, 2000  
Page 3

No fee is deemed necessary in connection with the filing of this response. However, if any additional fee is required, Applicants hereby authorize the Patent Office to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Sarah B. Adriano", is written over a horizontal line.

Sarah B. Adriano  
Reg. No. 34,470  
SaraLynn Mandel  
Reg. No. 31,853  
Mandel & Adriano  
55 S. Lake Avenue, Suite 710  
Pasadena, California 91101  
(626) 395-7801  
Customer No. 26,941